Pediatric Cancer Clinical Trials 2022

Pediatric Cancer studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect pediatric cancer clinical trial in 2022.

Condition

Location

Distance

Age

Clinical Trials Pediatric Cancer Clinical Trials 2022

Phase-Based Progress Estimates

Dinutuximab With Chemotherapyfor Neuroblastoma

Los Angeles, CA

Waitlist Available

Los Angeles, CA

Studies have shown that the anti-GD2 human-mouse chimeric monoclonal antibody dinutuximab has contributed significantly to the improvement of treatment for children with high-risk neuroblastoma and has become a mainstay in treating high risk neuroblastoma in children as part of up-front therapy and relapsed/refractory therapy. The administration of dinutuximab requires a significant amount of time and resources to complete the 10-20 hour standard infusion time for 4 days in the inpatient setting. During its early development, a phase I study profiling the clinical efficacy and tolerability of dinutuximab infusions in children successfully infused dinutuximab at various rates including over 1 hour at different dose levels. In the adult setting, dinutuximab has been tolerated over substantially shorter infusion times (less than 2 hours). Additionally, another anti-GD2 murine monoclonal antibody naxitamab, which has a similar toxicity profile to dinutuximab, is FDA approved for administration over 90 minutes and is successfully administered in outpatient setting. Given this reassuring data we aim to evaluate the feasibility of the rapid administration of dinutuximab over four hours or less in our patient population of children with high-risk neuroblastoma. The pharmacokinetics, toxicity profile and supportive care requirements will be analyzed and described in order to determine if rapid infusion of dinutuximab can be successfully tolerated over four hours or less which would allow for administration of this agent in the outpatient setting. Should this trial prove to be successful, it would serve to decrease the hospital burden in a positive way by allowing for administration of this immunotherapy agent in the outpatient setting and patients may prefer shorter infusion duration. Furthermore, it could lessen overall costs and inpatient admissions for patients.

Phase-Based Progress Estimates

Clinician Barrier Reportsfor Adherence, Medication

To develop a cancer center level practice intervention to promote treatment adherence and reduce outcome disparities in pediatric cancer survivors

Phase-Based Progress Estimates

Adaptive Attention Trainingfor Pediatrics Cancer

San Francisco, CA

Waitlist Available

San Francisco, CA

This study is evaluating whether a novel, adaptive attention training can improve cognitive and behavioral outcomes in pediatric cancer survivors.

Phase-Based Progress Estimates

Cyclophosphamidefor Neuroblastoma

This study is evaluating whether a drug called N9 is safe and effective for children with neuroblastoma.

Phase-Based Progress Estimates

Healthy Lifestylesfor Pediatrics Cancer

Saint Petersburg, FL

Waitlist Available

1 Prior Treatment

Saint Petersburg, FL

This study is evaluating whether a healthy lifestyle intervention may help improve the health of adolescent and young adult survivors of pediatric cancer.

Phase-Based Progress Estimates

Tranexamic Acidfor Limb Salvage

This is a randomized double-blind control trial evaluating the use Tranexamic acid (TXA) to decrease blood loss and transfusion requirements in pediatric and young adult cancer patients undergoing a limb salvage procedure that frequently requires perioperative or post-operative transfusions of blood products. Primary Objective To evaluate the difference in intra-or post-operatively transfused blood volume (mL/kg) for patients undergoing limb salvage procedures of the distal femur or proximal tibia who are randomized to receive perioperative tranexamic acid (TXA) versus placebo. Secondary Objectives To evaluate changes in platelets and in hemoglobin from pre-op to post-op level for patients randomized to receive perioperative TXA versus placebo. To evaluate differences in post-operative daily surgical drain output for patients randomized to receive perioperative TXA versus placebo. To evaluate changes in estimated blood loss (EBL) for patients randomized to receive perioperative TXA versus placebo. To evaluate the association between the intra-or post-operatively transfused blood volume and estimated blood loss (EBL) for patients randomized to receive perioperative TXA and placebo, respectively. Exploratory Objectives To evaluate differences in functional outcomes post-operatively for patients randomized to receive perioperative TXA versus placebo. To explore if significant correlations are observed between parameters reported with rotational thromboelastometry (ROTEM®) and EBL and transfusion requirements in pediatric and young adult patients undergoing limb salvage procedure who are randomized to perioperative TXA versus placebo. To evaluate differences in the prevalence and management of wound complications such as superficial or periprosthetic infections, wound dehiscence, contact dermatitis, post- operative hematomas, or any other clinically significant wound complication between patients randomized to receive perioperative TXA versus placebo.

Phase-Based Progress Estimates

Panitumumab-IRDye800for Neoplasms, Brain

Waitlist Available

This study is evaluating whether a drug used to treat cancer may be safe for use in children.

Phase-Based Progress Estimates

BMS-986158for Lymphoma

This study is evaluating whether a drug may help treat children with cancer.

Phase-Based Progress Estimates

Granulocyte Colony-Stimulating Factorfor Neutropenia

Waitlist Available

This study is evaluating whether a medication given after chemotherapy can help reduce the risk of infection.

Phase-Based Progress Estimates

ALRN-6924for Lymphoma

Philadelphia, PA

Philadelphia, PA

This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia. The drugs involved in this study are: ALRN-6924 Cytarabine (for patients with leukemia only)

Phase-Based Progress Estimates

Optune NovoTTF-200A Systemfor Ependymoma

This study is evaluating whether a device which delivers alternating electric fields to the brain may help treat children with recurrent brain tumors.

Phase-Based Progress Estimates

Indocyanine Green (ICG)for Pediatric Patients With Solid Tumors

Waitlist Available

This study is being done in patients that have tumors to find out how well sentinel lymph nodes (SLNs) can be found with a special dye called indocyanine green (ICG).

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service